A Phase 1 Study of JNJ-89862175, an Antibody Drug Conjugate (ADC) Agent Targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 (ENPP3), for Advanced Solid Tumors

  • Enrollment

    This study is not currently enrolling.

  • Research Area

    Clinical Cancer Research

  • Sponsor

    Janssen Research & Development, LLC